Show All

August 2011

Cohen JD, Babiarz JE, Abrams RM, Guo L, Kameoka S, Chiao E, Taunton J, and Kolaja KL

Use of Human Stem Cell-derived Cardiomyocytes to Examine Sunitinib Mediated Cardiotoxicity and Electrophysiological Alterations

Toxicol Appl Pharmacol 257(1):74-83

Publication Date: August 27, 2011

Product Type: iCell Cardiomyocytes


Elucidation of the molecular mechanisms of sunitinib-induced cardiotoxicity using iCell Cardiomyocytes revealed, contrary to previous data using rodent models, that AMPK and RSK do not play a significant role.


This study illustrates the limitations of non-human model systems and the benefit and importance of using a human cell-based model system to detect and study human cardiotoxicity.

Meyer JS, Howden SE, Wallace KA, Verhoeven AD, Wright LS, Capowski EE, Pinilla I, Martin JM, Tian S, Stewart R, Pattnaik B, Thomson JA, and Gamm DM

Optic Vesicle Structures Derived from Human Pluripotent Stem Cells Facilitate a Customized Approach to Retinal Disease Treatment

Stem Cells 29(8):1206-18

Publication Date: August 22, 2011

Product Type: CDI Technology


Demonstration that three-dimensional populations of retinal progenitor cells (RPCs) can be isolated from early forebrain populations in both human embryonic stem cell and hiPSC cultures, providing a valuable tool for developmental, functional, and translational studies. Using the established protocol, a transient population of optic vesicle (OV)-like structures that arose during a time period appropriate for normal human retinogenesis were identified.

July 2011

Rajesh D, Dickerson SJ, Yu J, Brown ME, Thomson JA, and Seay NJ

Human Lymphoblastoid B Cell Lines Reprogrammed to EBV-free Induced Pluripotent Stem Cells

Blood 118(7):1797-1800

Publication Date: July 27, 2011

Product Type: CDI Technology


Generation of iPSCs from two LCLs via a feeder-free episomal method using a cocktail of transcription factors and small molecules. LCL-derived iPSCs exhibited normal karyotype, expressed pluripotency markers, lost oriP/EBNA-1 episomal vectors, generated teratomas, retained donor identity and differentiated in vitro into hematopoietic, cardiac, neural, and hepatocyte-like lineages.

June 2011

Guo L, Abrams RM, Babiarz JE, Cohen JD, Kameoka S, Sanders MJ, Chiao E, and Kolaja KL

Estimating the Risk of Drug-induced Proarrhythmia Using Human Induced Pluripotent Stem Cell-derived Cardiomyocytes

Toxicol Sci 123(1):281-9

Publication Date: June 20, 2011

Product Type: iCell Cardiomyocytes


Analysis of 28 compounds with known cardiac effects was performed using iCell Cardiomyocytes and the xCELLigence RTCA Cardio System. Compound-specific changes in cardiac beat rate and/or the amplitude of the impedance measurement were consistent with clinical findings. The results were confirmed using iCell Cardiomyocytes and a multielectrode array (MEA) platform.


iCell Cardiomyocytes responded to known cardiotoxic compounds in a manner consistent with clinical observations. Analysis was performed using two cell analysis platforms commonly used in the pharmaceutical industry.

Guo L, Qian JY, Abrams R, Tang HM, Weiser T, Sanders MJ, and Kolaja KL

The Electrophysiological Effects of Cardiac Glycosides in Human iPSC-derived Cardiomyocytes and in Guinea Pig Isolated Hearts

Cell Physiol Biochem 27(5):453-62

Publication Date: June 15, 2011

Product Type: iCell Cardiomyocytes


Pharmacological and toxicological effects of cardiac glycosides (ouabain, digoxin) and the L-type Ca2+ channel antagonist nifedipine were measured in iCell Cardiomyocytes using a multielectrode array (MEA) platform. The observed changes in field potential duration and Ca2+ wave amplitude correlated with the compounds’ effects on QT interval and contractility in guinea pig Langendorff hearts.


iCell Cardiomyocytes showed expected pharmacological and toxicological responses to compounds known to disrupt cardiac cell function through a variety of biochemical mechanisms

May 2011

Chen G, Gulbranson DR, Hou Z, Bolin JM, Ruotti V, Probasco MD, Smuga-Otto K, Howden SE, Diol NR, Propson NE, Wagner R, Lee GO, Antosiewicz-Bourget J, Teng JM, and Thomson JA

Chemically Defined Conditions for Human iPS Cell Derivation and Culture

Nat Methods 8(5):424–429

Publication Date: May 8, 2011

Product Type: CDI Technology


Use of new medium (E8) and vitronectin-coated surfaces to demonstrate improved derivation efficiencies of vector-free human iPS cells with an episomal approach.

Slukvin II and Vodyanik M

Endothelial Origin of Mesenchymal Stem Cells

Cell Cycle 10(9):1370-3

Publication Date: May 1, 2011

Product Type: CDI Technology


Demonstrating that mesodermal MSCs arise from APLNR+ precursors with angiogenic potential, mesenchymoangioblasts.

March 2011

Anson BD, Kolaja KL, and Kamp TJ

Opportunities for Use of Human iPS Cells in Predictive Toxicology

Clin Pharmacol Ther 89(5):754-758

Publication Date: March 23, 2011

Product Type: CDI Technology


Description of the properties of human induced pluripotent stem (iPS) cells that make them a promising source for toxicity assessment, highlight the progress to date, and point out the important roadblocks that remain.

Howden SE, Gore A, Li Z, Fung HL, Nisler BS, Nie J, Chen G, McIntosh BE, Gulbranson DR, Diol NR, Taapken SM, Vereide DT, Montgomery KD, Zhang K, Gamm DM, and Thomson JA

Genetic Correction and Analysis of Induced Pluripotent Stem Cells from a Patient with Gyrate Atrophy

Proc Natl Acad Sci USA 108(16):6537-6542

Publication Date: March 1, 2011

Product Type: CDI Technology


Isolation of iPS cells free of transgene sequences from a patient with gyrate atrophy caused by a point mutation in the gene encoding ornithine-δ-aminotransferase (OAT) and use of homologous recombination to correct the genetic defect.

Yu J, Chau KF, Vodyanik MA, Jiang J, and Jiang Y

Efficient Feeder-free Episomal Reprogramming with Small Molecules

PLoS One 6(3):e17557

Publication Date: March 1, 2011

Product Type: CDI Technology


Establishment of a feeder-free reprogramming condition using chemically defined medium with bFGF and N2B27 supplements and chemically defined human ESC medium mTeSR1 for the derivation of footprint-free human iPSCs.

February 2011

Hu K, Yu J, Suknuntha K, Tian S, Montgomery K, Choi KD, Stewart R, Thomson JA, and Slukvin II

Efficient Generation of Transgene-free Induced Pluripotent Stem Cells from Normal and Neoplastic Bone Marrow and Cord Blood Mononuclear Cells

Blood 117(14):e109-19

Publication Date: February 4, 2011

Product Type: CDI Technology


Demonstrated that iPSCs free of transgene and vector sequences could be efficiently generated from human bone marrow (BM) and cord blood (CB) mononuclear cells using non-integrating episomal vectors.

June 2010

Brown ME, Rondon E, Rajesh D, Mack A, Lewis R, Feng X, Zitur LJ, Learish RD, and Nuwaysir EF

Derivation of Induced Pluripotent Stem Cells from Human Peripheral Blood T Lymphocytes

PLoS One 5(6):e11373

Publication Date: June 29, 2010

Product Type: CDI Technology


Generation of T lymphocyte-derived iPSCs from small, clinically advantageous volumes of non-mobilized peripheral blood. These T-cell derived iPSCs retain a normal karyotype and genetic identity to the donor.

June 2009

Yu J and Thomson JA

Induced Pluripotent Stem Cell Derivation

Essentials of Stem Cell Biology, 2nd edition, Elsevier Academic Press

Publication Date: June 5, 2009

Product Type: CDI Technology


Description of basic biology/mechanisms, early development, ectoderm, mesoderm, endoderm, methods to application of stem cells to specific human diseases, regulation and ethics, and patient perspectives, and more in the field of stem cells.

May 2009

Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, and Thomson JA

Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences

Science 324(5928):797-801

Publication Date: May 8, 2009

Product Type: CDI Technology


Derivation of human iPS cells with the use of nonintegrating episomal vectors.

January 2009

Ebert AD, Yu J, Rose FF Jr, Mattis VB, Lorson CL, Thomson JA, and Svendsen CN

Induced Pluripotent Stem Cells from a Spinal Muscular Atrophy Patient

Nature 457(7227):277-80

Publication Date: January 15, 2009

Product Type: CDI Technology


Generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy.

August 2008

Yu J and Thomson JA

Pluripotent Stem Cell Lines

Genes Dev 22(15):1987-97

Publication Date: August 1, 2008

Product Type: CDI Technology


Review of the family of pluripotent cell lines derived from early embryos and from germ cells, comparing them with more recently described induced pluripotent stem cells.

December 2007

Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, and Thomson JA

Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells

Science 318(5858):1917-20

Publication Date: December 21, 2007

Product Type: CDI Technology


Showing that four factors (OCT4, SOX2, NANOG, and LIN28) are sufficient to reprogram human somatic cells to pluripotent stem cells that exhibit the essential characteristics of embryonic stem cells.

January 2006

Yu J, Vodyanik MA, He P, Slukvin II, and Thomson JA

Human Embryonic Stem Cells Reprogram Myeloid Precursors Following Cell-Cell Fusion

Stem Cells 24(1):168-76

Publication Date: January 24, 2006

Product Type: CDI Technology


Reprogramming of the nuclei of hESC-derived myeloid precursors following cell-cell fusion.

Pageof 4